Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Gene therapeutics developer bluebird nets $108mm through its IPO

25 Jun 2013

Executive Summary

Bluebird bio Inc., developer of gene transfer therapeutics, has netted $108mm through its initial public offering of 6.8mm common shares (including the overallotment) at $17. Just days before the final pricing, it had proposed selling 5mm shares between $14-16.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By